AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16934685
Drug: Oltipraz 500
RxNorm normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oltipraz 500 mg weekly
Trial: 9457093
Drug: Early amniocentesis
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early amniocentesis (11 mL, between 11(+0) and 12(+6) gestational weeks)
Trial: 9457093
Drug: Midtrimester amniocentesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midtrimester amniocentesis (20 mL, between 15(+0) and 16(+6) gestational weeks)
Trial: 8572639
Drug: Treatment A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A: 1 mg of GRAN initially and 12 hours after the first dose
Trial: 8572639
Drug: Treatment B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B: a single 2 mg dose of GRAN
Trial: 1023957
Drug: Doxapram 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram 250 mg in dextrose 5%
Trial: 20849938
Drug: BGP-15 (400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGP-15 (400mg once daily for 17 days)
Trial: 18179312
Drug: Visually-impoverished environment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visually-impoverished environment training under alcohol (0.65 g/kg)
Trial: 18179312
Drug: Normal visual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal visual environment training under alcohol (0.65 g/kg)
Trial: 10682110
Drug: GDP-free PD
RxNorm normalized name: Poly Hist PD
DrugBank: Thonzylamine (DB11235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDP-free PD solution
Trial: 24711637
Drug: Conventional PD
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional PD solution
Trial: 2283647
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg (10 patients) and 20 mg (2 patients) twice daily for 8 weeks
Trial: 23896377
Drug: Adjuvant PCV
RxNorm normalized name: PCV
DrugBank: Penciclovir (DB00299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant PCV (Procarbazine, CCNU, Vincristine) chemotherapy
Trial: 15151167
Drug: Acetaminophen (1g)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1g) administered after zobo drink
Trial: 15151167
Drug: Acetaminophen (1g)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1g) administered alone
Trial: 9832115
Drug: High-dose lisinopril-isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose lisinopril-isosorbide dinitrate therapy
Trial: 9832115
Drug: Established doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Established doses of angiotensin-converting enzyme inhibitor and nitrate therapy
Trial: 2561096
Drug: Oral Glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Glucose Tolerance Test (O‐GTT)
Trial: 2561096
Drug: Insulin Secretion
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin Secretion Test (IST)
Trial: 31984598
Drug: Tirzepatide 12
RxNorm normalized name: tirzepatide 12.5 MG in 0.5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide 12 mg
Trial: 31984598
Drug: Tirzepatide 15
RxNorm normalized name: tirzepatide 15 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide 15 mg-1
Trial: 31984598
Drug: Tirzepatide 15
RxNorm normalized name: tirzepatide 15 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide 15 mg-2
Trial: 23262999
Drug: GS-9851 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-9851 (25 to 800 mg)
Trial: 21636183
Drug: Oral essential
RxNorm normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral essential amino acids 4 gr 2 times a day for 8 weeks
Trial: 18175066
Drug: E+L+ (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E+L+ (10 + 50 mg/day)
Trial: 18175066
Drug: L+ (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L+ (50 mg/day)
Trial: 17205814
Drug: Shenle Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenle Capsule (SC)
Trial: 14638484
Drug: Linezolid (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (600 mg)
Trial: 9046509
Drug: Traditional non-operative
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional non-operative therapy
Trial: 1951149
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement given twice a day providing an average of 10.66 kJ (400 kcal) and 5 g protein/d.
Trial: 1951149
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no dietary supplement).
Trial: 26247967
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acid supplementation (EPA + DHA) at varying doses (Study 1: 0, 300, 600, 900, and 1800 mg/day; Study 2: 0, 850, and 3400 mg/day)
Trial: 17611715
Drug: Paclitaxel alone
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel alone (total cumulative dose range: 950‐2,475 mg/m2)
Trial: 17611715
Drug: Paclitaxel and
RxNorm normalized name: paclitaxel and encequidar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel and adriamycin (total cumulative dose range: 700‐2,800 mg/m2)
Trial: 21241447
Drug: Laughter therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laughter therapy
Trial: 7698890
Drug: high‐dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high‐dose methylprednisolone
Trial: 7698890
Drug: low‐dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low‐dose methylprednisolone
Trial: 3661613
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g)
Trial: 3661613
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g) with indomethacin (50 mg) pretreatment
Trial: 3661613
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg) pretreatment
Trial: 29106749
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment simultaneous to periodontal treatment
Trial: 29106749
Drug: Cause-related periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cause-related periodontal treatment before orthodontic treatment (Control)
Trial: 22416849
Drug: Rilpivirine (RPV;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilpivirine (RPV; TMC278) 25 mg once a day
Trial: 22416849
Drug: Efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz (EFV) 600 mg once a day
Trial: 1447645
Drug: DTP‐Ac vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP‐Ac vaccine
Trial: 26667034
Drug: Cannabis (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis (450 μg/kg THC)
Trial: 24106872
Drug: Cocaine HCl
RxNorm normalized name: cocaine HCl
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine HCl (300 mg)
Trial: 23106987
Drug: Unimanual constraint‐induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unimanual constraint‐induced movement therapy (CIMT)
Trial: 18046973
Drug: Zofenopril 30
RxNorm normalized name: zofenopril 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zofenopril 30 mg once daily (titration 60 mg od)
Trial: 18046973
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg once daily (titration 100 mg od)
Trial: 18046973
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events related to study medications
Trial: 12522468
Drug: perindopril 4
RxNorm normalized name: perindopril 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perindopril 4 mg
Trial: 10547552
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (50 mg every other day)
Trial: 8697725
Drug: Gel-DAT
RxNorm normalized name: Otic Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel-DAT
Trial: 6203312
Drug: Anthralin treatment
RxNorm normalized name: Anthralin
DrugBank: Anthralin (DB11157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthralin treatment once or twice a week after healing
Trial: 6203312
Drug: Anthralin treatment
RxNorm normalized name: Anthralin
DrugBank: Anthralin (DB11157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthralin treatment combined with UV irradiation
Trial: 6203312
Drug: Anthralin treatment
RxNorm normalized name: Anthralin
DrugBank: Anthralin (DB11157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthralin treatment
Trial: 29513699
Drug: No pills
RxNorm normalized name: No Doz Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pills at all (Control)
Trial: 25269854
Drug: Olopatadine HCl
RxNorm normalized name: olopatadine HCl
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olopatadine HCl ophthalmic solution 0.1%
Trial: 25269854
Drug: Epinastine HCl
RxNorm normalized name: epinastine HCl
DrugBank: Epinastine (DB00751)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epinastine HCl ophthalmic solution 0.05%
Trial: 16236859
Drug: Aminophylline 225
RxNorm normalized name: aminophylline 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline 225 mg bid po for 8 weeks (group 1)
Trial: 16236859
Drug: Aminophylline 225
RxNorm normalized name: aminophylline 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline 225 mg bid po for 8 weeks (group 2)
Trial: 16236859
Drug: Aminophylline 225
RxNorm normalized name: aminophylline 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline 225 mg bid po for 8 weeks (both groups)
Trial: 9933750
Drug: Evening primrose
RxNorm normalized name: EVENING PRIMROSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening primrose oil (EPO) 2 g/day for 6 weeks
Trial: 9933750
Drug: Linoleic acid
RxNorm normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linoleic acid (LA) 2 g/day for 6 weeks
Trial: 2186867
Drug: Pharmacologic therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic therapies (e.g., low-dose diuretics such as Chlorthalidone, 12.5 or 25 mg per day)
Trial: 23131078
Drug: Pharmacologic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic therapy
Trial: 2186867
Drug: Low-dose diuretics
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose diuretics
Trial: 2186867
Drug: Other agents
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other agents (beta-blockers, reserpine, ACE inhibitors, calcium channel blockers)
Trial: 355960
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous carbenicillin (administered preoperatively and continued for 24 hours)
Trial: 355960
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic antibiotics (control)
Trial: 25887344
Drug: Primaquine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine combined with dihydroartemisinin-piperaquine (three different single doses)
Trial: 20004499
Drug: Estrogen treatment
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen treatment for 12 weeks
Trial: 15589857
Drug: HMR 3339
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMR 3339 (10 mg)
Trial: 15589857
Drug: HMR 3339
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMR 3339 (50 mg)
Trial: 15589857
Drug: HMR 3339
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMR 3339 (2.5 mg)
Trial: 7915625
Drug: Chronic beta‐adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic beta‐adrenergic blocking therapy (study group)
Trial: 7915625
Drug: No beta‐blocking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta‐blocking therapy (control group)
Trial: 8815556
Drug: Mepartricin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepartricin at a dose of 150,000 U, administered once a day in the evening for 6 months
Trial: 6524275
Drug: Intramuscular oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular oxycodone and/or metamizol (IM)
Trial: 6524275
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 4 mg (EM)
Trial: 6524275
Drug: i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of fentanyl 0.54‐0.99 micrograms min‐1 + on-demand boluses of 7.2‐13.5 micrograms (ODAC)
Trial: 27129139
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy performed twice a week
Trial: 25112009
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia by lidocaine (1%) combined with midazolam (0.04 mg/kg) intravenous sedation
Trial: 19618315
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/d combined with aspirin 100 mg/d
Trial: 19618315
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of aspirin 100 mg/d
Trial: 19332730
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg
Trial: 12106935
Drug: Acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine (600 mg orally twice daily) with 0.45% saline intravenously (group A)
Trial: 2206783
Drug: Enalapril 10‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10‐40 mg once daily
Trial: 2206783
Drug: Nifedipine retard
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine retard 10‐40 mg twice daily
Trial: 2206783
Drug: Hydrochlorothiazide 12.5‐50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5‐50 mg once daily (added for inadequate responders)
Trial: 27611077
Drug: Brincidofovir 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brincidofovir 200 mg loading dose on day 0, followed by 100 mg on days 3, 7, 10, and 14 (bodyweight-adjusted for patients <50 kg).
Trial: 21926599
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion for blood glucose control to 80-110 mg/dL
Trial: 21926599
Drug: Conventional glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glucose management (insulin administered only when glucose levels rose above 215 mg/dL)
Trial: 15310081
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 to 100 mg/d
Trial: 15310081
Drug: Valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 to 160 mg/d
Trial: 7811043
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate (528 mg, 30 ml of Pepto-Bismol)
Trial: 7811043
Drug: Ciprofloxacin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (750 mg)
Trial: 3290706
Drug: CR4-Sinemet (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR4-Sinemet (twice daily)
Trial: 25382074
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab injection (IVBI) 1.25 mg at baseline and pro re nata based on ME presence; follow-up for 12 months.
Trial: 25382074
Drug: Subthreshold grid
RxNorm normalized name: MINERAL OIL 100 g in 100 mL TOPICAL LIQUID [THE GRID]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subthreshold grid laser treatment (SGLT) administered once; follow-up for 12 months.
Trial: 23441791
Drug: Er,Cr:YSGG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er,Cr:YSGG laser assisted pocket therapy (ELAPT)
Trial: 23441791
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (ELAPT and OFD)
Trial: 21855969
Drug: Propiverine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine treatment
Trial: 14603093
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of benzathine penicillin, azithromycin, and cefixime
Trial: 14603093
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of cefixime and 3 doses of azithromycin given biweekly
Trial: 11164425
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg bezafibrate once daily for 6 weeks
Trial: 9342067
Drug: GM-CSF (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF (300 microg subcutaneously daily for 1 week, then 150 microg subcutaneously two times weekly for 11 weeks)
Trial: 2870732
Drug: ICI 141,292
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 141,292 200 mg
Trial: 2870732
Drug: ICI 141,292
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 141,292 400 mg
Trial: 25721770
Drug: Ciprofloxacin-containing sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin-containing sequential therapy
Trial: 25721770
Drug: Clarithromycin-containing sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin-containing sequential therapy
Trial: 23715567
Drug: MAGE-A3 immunotherapy
RxNorm normalized name: Kitasamycin A3
DrugBank: Josamycin (DB01321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAGE-A3 immunotherapy (n = 122)
Trial: 20860413
Drug: Colesevelam plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam plus low-dose statin or niacin
Trial: 20860413
Drug: Colesevelam (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam (1.5 g/day to 3.75 g/day)
Trial: 15940147
Drug: Beta-methasone-17-valerate (BMV)
RxNorm normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta-methasone-17-valerate (BMV) cream 0.1%
Trial: 15940147
Drug: Matching vehicle
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching vehicle cream
Trial: 9088806
Drug: OLITA program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLITA program (Outpatient Long‐term Intensive Therapy for Alcoholics)
Trial: 1534047
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once daily in the morning for seven days
Trial: 1534047
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once daily in the evening for seven days
Trial: 1534047
Drug: Lansoprazole (morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (morning and evening dosing)
Trial: 30736761
Drug: Non-operative shoulder
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative shoulder exercise treatment (not specified dosage or duration)
Trial: 30736761
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not receiving non-operative shoulder treatment)
Trial: 25241755
Drug: T-PEMF once
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-PEMF once daily (active dose in the morning and sham in the afternoon)
Trial: 25241755
Drug: T-PEMF twice
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: T-PEMF twice daily (active dose both morning and afternoon)
Trial: 18931219
Drug: NMBAS-guided rocuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMBAS-guided rocuronium administration
Trial: 11707843
Drug: EPOCH chemotherapy
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPOCH chemotherapy (etoposide/doxorubicin/vincristine/cyclophosphamide/prednisone)
Trial: 19204798
Drug: EPOCH chemotherapy
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPOCH chemotherapy
Trial: 9203934
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg twice daily for four weeks
Trial: 7692755
Drug: Therapy for
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy for recurrent malignant neoplasia (pure yolk sac tumor or teratoma with yolk sac elements)
Trial: 3114808
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg alprazolam PO daily as 2 mg bid